Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at Biocept, Becton Dickinson, Thermo Fisher, More

Biocept: Samuel Riccitelli, Antonino Morales

Biocept has appointed Samuel Riccitelli as its interim president and CEO and Antonino Morales as its interim CFO. The two hires succeed Michael Nall and Timothy Kennedy, respectively, who resigned their positions on Feb. 15. The firm also named Faye Wilson as lead independent director of the company’s board of directors.

Riccitelli, who remains chair of Biocept's board, joined the firm in October 2020. He has more than 35 years' experience in the healthcare industry, including as a member of the board for Orthopediatrics. He also served as CEO of Pathnostics from 2019 to 2020 and as the board chair for Precipio from 2017 to 2019. Prior to that, Riccitelli served as president and CEO of Signal Genetics, as executive VP and chief operating officer of Genoptix, and in a number of R&D and general management leadership positions for Becton Dickinson.

Morales, a certified public accountant, has served as a member of Biocept's board since July 2021 and as a member of the firm's audit committee from August 2021 until his latest appointment. He served as president and CEO of Apoyo Financiero from June 2017 to March 2020 and has served in multiple senior management or consulting roles with various Fortune 100 companies including Citibank, Bank of America, Arthur Andersen, and Mazda North America.

Biocept said it entered into separation agreements with Nall and Kennedy, pursuant to which each of them has agreed to provide the firm with a full release of claims. Biocept has also agreed to provide Nall and Kennedy with the severance benefits they would have been entitled to receive under their respective employment agreements in the event of a termination without cause.

Becton Dickinson: Shana Neal

Becton Dickinson has appointed Shana Neal to the role of chief people officer, effective April 4. 

Neal held human resources leadership positions at BD from 2005 to 2018. She most recently served as executive VP and chief human resources officer at healthcare solutions company Owens & Minor, as well as president of the Owens & Minor Foundation and the firm's executive sponsor for environmental, social, and governance initiatives. Neal will now oversee BD's human resources, communications, and social investing functions globally, and will report to BD's chairman, CEO, and president, Tom Polen. She replaces Betty Larson, who has been named to a new role in the healthcare industry.

Thermo Fisher Scientific: Ruby Chandy

Ruby Chandy has been elected to the board of directors of Thermo Fisher Scientific, effective March 1. Her appointment will bring the total number of board members to 13. Chandy was the president of the industrial division at Pall, a supplier of filtration, separation, and purification technologies. Previously, she was chief marketing officer at Dow Chemical and at Rohm and Haas. She holds a master's degree from the Massachusetts Institute of Technology Sloan School, a master's degree in materials science and engineering from Northwestern University, and a bachelor's degree in materials science and engineering from MIT.

For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.